Evidence for a limited growth hormone (GH)-releasing hormone (GHRH)-releasable quantity of GH: effects of 6-hour infusions of GHRH on GH secretion in normal man.

Human GH-releasing hormone [hGHRH-40 (GHRH)] stimulates GH release in a dose-dependent fashion when administered as single iv bolus doses or as continuous 90-min infusions. However, there has been variability in the GH responses, and it appears that there are waxing and waning effects of GHRH. To address whether these are a result of the dose of GHRH, time, or intermittent changes in sensitivity of the somatotrophs, we administered 6-h infusions of vehicle and different doses of GHRH to six normal men. In addition, an iv bolus injection of GHRH was given after 5.5 h of infusion to evaluate residual GH secretory capacity. The subjects were given infusions of either vehicle or GHRH (1, 3.3, and 10 ng/kg X min), followed by an iv bolus injection of 3.3 micrograms/kg on four separate occasions. GHRH infusions stimulated GH secretion compared to basal secretion. The changes from basal GH secretion (mean +/- SEM) were 2.0 +/- 1.6, 4.6 +/- 1.5, 12.7 +/- 5.1, and 8.2 +/- 1.8 ng/ml X h during the vehicle and GHRH (1, 3.3, and 10 ng/kg X min) infusions, respectively. The changes from basal GH secretion for 2 h after the iv bolus dose (after 5.5 h of infusion) were 33.3 +/- 8.7, 22.4 +/- 3.8, 14.0 +/- 3.6, and 10.5 +/- 2.0 ng/ml X h on the vehicle and GHRH (1, 3.3, and 10 ng/kg X min) infusion days, respectively. The magnitude of the GH response was inversely related to the GHRH infusion dose. The total amount of GH released during the 7.5-h study periods was not different among the vehicle and 3 GHRH infusion days. Thus, it appears that a finite amount of GH is released by GHRH. There was variability in the degree of responsiveness to the continuous infusions of GHRH. Surges of GH release occurred during the GHRH infusions, which may be attributed to intermittent secretion of a GH inhibitor, such a somatostatin.

[1]  M. Vance,et al.  Plasma growth hormone responses to constant infusions of human pancreatic growth hormone releasing factor. Intermittent secretion or response attenuation. , 1984, The Journal of clinical investigation.

[2]  N. Ling,et al.  Pituitary growth hormone response in rats during a 24-hour infusion of growth hormone-releasing factor. , 1984, Endocrinology.

[3]  M. Vance,et al.  Human pancreatic tumor growth hormone-releasing factor: dose-response relationships in normal man. , 1984, The Journal of clinical endocrinology and metabolism.

[4]  M. Vance,et al.  Metabolic clearance and plasma disappearance rates of human pancreatic tumor growth hormone releasing factor in man. , 1984, The Journal of clinical investigation.

[5]  M. Vance,et al.  Intranasal administration of human pancreatic tumor GH-releasing factor-40 stimulates GH release in normal men. , 1983, The Journal of clinical endocrinology and metabolism.

[6]  M. Molitch,et al.  Human growth hormone and somatomedin C suppress the spontaneous release of growth hormone in unanesthetized rats. , 1983, Endocrinology.

[7]  R. Guillemin,et al.  Synthetic human pancreas growth hormone-releasing factor (hpGRF1-44-NH2) stimulates growth hormone secretion in normal men. , 1983, The Journal of clinical endocrinology and metabolism.

[8]  M. Vance,et al.  HUMAN PANCREATIC GROWTH-HORMONE-RELEASING FACTOR SELECTIVELY STIMULATES GROWTH-HORMONE SECRETION IN MAN , 1983, The Lancet.

[9]  N. Ling,et al.  Physiological roles of somatocrinin and somatostatin in the regulation of growth hormone secretion. , 1982, Biochemical and biophysical research communications.

[10]  R. Clayton Gonadotropin-releasing hormone modulation of its own pituitary receptors: evidence for biphasic regulation. , 1982, Endocrinology.

[11]  L. Frohman,et al.  Effects of growth hormone excess and deficiency on hypothalamic somatostatin content and release and on tissue somatostatin distribution. , 1981, Endocrinology.

[12]  R L Hintz,et al.  Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. , 1981, Science.

[13]  K. Copeland,et al.  Induction of immunoreactive somatomedin C human serum by growth hormone: dose-response relationships and effect on chromatographic profiles. , 1980, The Journal of clinical endocrinology and metabolism.

[14]  R. Furlanetto,et al.  Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. , 1977, The Journal of clinical investigation.

[15]  L. Frohman,et al.  Metabolic clearance and production rates of human growth hormone in subjects with normal and abnormal growth. , 1970, The Journal of clinical endocrinology and metabolism.

[16]  E. Knobil,et al.  The neuroendocrine control of the menstrual cycle. , 1980, Recent progress in hormone research.

[17]  H. Lebovitz,et al.  Growth hormone releasing action of a Pseudomonas endotoxin (piromen). , 1967, Metabolism: clinical and experimental.